The ongoing goals of CORE A will be: 1) to provide generalized administrative support, 2) to insure efficient and appropriate usage of core services by the individual projects, 3) to coordinate and organize monthly research meetings of the program investigators, 4) to provide mechanisms of conflict resolution and potential rebudgeting issues, 5) to provide constructive review of the research through Internal and External advisory committees, 6) to provide budgetary services, such as tracking the expenditures of the program and providing monthly reports to the investigators, 7) to provide an objective quality assurance program that will monitor the clinical trials, and 8) to provide assistance and coordination with regulatory agencies within the Penn campus and with the FDA and R.A.C. The administrative functions (Goals 1-5) will be accomplished using a structure in which the Core Leader, Dr. Albelda, is advised by an Executive Committee of Project and Core Leaders with input from Internal and External Advisory Committees. He will be assisted by an administrative assistant, Ms. Pelzer. The budgetary goal (Goal 6) will be performed by Ms. Lavinia Pritchett. She will be responsible for facilitating communication and will have budgetary responsibility with oversight from Dr. Albelda. To provide an objective quality assurance program that will monitor the clinical trials, and to provide assistance and coordination with regulatory agencies within the PENN campus and with the FDA and R.A.C. (Goals 7 and 8), the Core will continue to utilize Penn's Office of Human Research and a regulatory consultant, Mr. Phillip Cross.
Malignant mesothelioma is currently considered incurable. New approaches are needed. This Core provides the administrative infrastructure to support the clinical and preclinical studies of the Program Project.
|Maus, Marcela V; Fraietta, Joseph A; Levine, Bruce L et al. (2014) Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol 32:189-225|
|Singh, Nathan; Liu, Xiaojun; Hulitt, Jessica et al. (2014) Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma. Cancer Immunol Res 2:1059-70|
|Wang, Liang-Chuan S; Lo, Albert; Scholler, John et al. (2014) Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res 2:154-66|
|Barrett, David M; Singh, Nathan; Liu, Xiaojun et al. (2014) Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. Cytotherapy 16:619-30|
|Moon, Edmund K; Wang, Liang-Chuan; Dolfi, Douglas V et al. (2014) Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res 20:4262-73|
|Beatty, Gregory L; Haas, Andrew R; Maus, Marcela V et al. (2014) Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2:112-20|
|Vonderheide, Robert H; June, Carl H (2014) Engineering T cells for cancer: our synthetic future. Immunol Rev 257:7-13|
|Fridlender, Z G; Jassar, A; Mishalian, I et al. (2013) Using macrophage activation to augment immunotherapy of established tumours. Br J Cancer 108:1288-97|
|Baek, Kwan-Hyuck; Bhang, Dongha; Zaslavsky, Alexander et al. (2013) Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors. J Clin Invest 123:4375-89|
|Quatromoni, Jon G; Suzuki, Eiji; Okusanya, Olugbenga et al. (2013) The timing of TGF-* inhibition affects the generation of antigen-specific CD8+ T cells. BMC Immunol 14:30|
Showing the most recent 10 out of 66 publications